Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Preferred Stock Liabilities (2022 - 2024)

Insight Molecular Diagnostics' Preferred Stock Liabilities history spans 3 years, with the latest figure at $5.3 million for Q1 2024.

  • For Q1 2024, Preferred Stock Liabilities fell 3.62% year-over-year to $5.3 million; the TTM value through Mar 2024 reached $5.3 million, down 3.62%, while the annual FY2023 figure was $5.1 million, 3.32% down from the prior year.
  • Preferred Stock Liabilities for Q1 2024 was $5.3 million at Insight Molecular Diagnostics, up from $5.1 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $5.5 million in Q1 2023 and bottomed at $4.7 million in Q2 2023.
  • The 3-year median for Preferred Stock Liabilities is $5.1 million (2023), against an average of $5.1 million.
  • The largest annual shift saw Preferred Stock Liabilities dropped 2.66% in 2023 before it dropped 3.62% in 2024.
  • A 3-year view of Preferred Stock Liabilities shows it stood at $5.3 million in 2022, then decreased by 3.32% to $5.1 million in 2023, then grew by 4.02% to $5.3 million in 2024.
  • Per Business Quant, the three most recent readings for IMDX's Preferred Stock Liabilities are $5.3 million (Q1 2024), $5.1 million (Q4 2023), and $4.9 million (Q3 2023).